文献速递哮喘

单日按需布地奈德-福莫特罗使用增加对轻度哮喘严重急性发作短期风险的影响:SYGMA 1 研究事后分析

Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.
PubMed 文献 · Lancet Respir Med · 2020-10-01

SYGMA 1 事后分析纳入 3836 例轻度哮喘患者,评估单日缓解药物吸入次数超过 2、4、6 或 8 次后 21 天内严重急性发作风险。与按需特布他林相比,按需布地奈德-福莫特罗在单日使用超过 2 次和 4 次后严重急性发作风险显著降低,即使总体使用不频繁。

要点

  • 轻度哮喘患者单日按需吸入超过 2 次后,按需布地奈德-福莫特罗较特布他林显著降低 21 天内严重急性发作风险。
  • 单日按需吸入超过 4 次后,按需布地奈德-福莫特罗同样显著降低严重急性发作风险。
  • 单日超过 6 次时风险降低无统计学显著性,超过 8 次因事件过少未计算 HR。

核心结论

  • 在轻度哮喘中,即使总体使用不频繁,按需布地奈德-福莫特罗可降低单日较高使用(超过 2 次按需吸入)后短期严重急性发作风险。

研究设计与样本

  • SYGMA 1 为 52 周双盲随机对照 3 期试验的事后分析,患者随机分为按需特布他林组、按需布地奈德-福莫特罗组和布地奈德维持组。
  • 共 3849 例患者随机分组,3836 例有可评估数据(按需特布他林 n=1277,按需布地奈德-福莫特罗 n=1277,布地奈德维持 n=1282)。
  • 评估单日缓解药物吸入超过 2、4、6 或 8 次后 21 天内严重急性发作风险。

主要发现

  • 单日超过 8 次按需吸入因事件数少未计算 HR。

临床怎么用

  • 轻度哮喘患者单日按需吸入超过 2 次时,使用按需布地奈德-福莫特罗可能降低后续 21 天内严重急性发作风险。

局限性

  • 本分析为事后分析,结果需在前瞻性随机临床试验中进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In mild asthma, as-needed budesonide-formoterol reduces long-term exacerbation risk compared with as-needed short-acting β2-agonist (SABA), with a similar or increased reduction versus maintenance with budesonide plus as-needed SABA, despite a lower budesonide dose. In this post-hoc analysis of the SYmbicort Given as needed in Mild Asthma (SYGMA) 1 study, we investigated the short-term risk of severe exacerbations after a single day with various levels of reliever use. METHODS: SYGMA 1 was a 52-week, double-blind, randomised, controlled, phase 3 trial, in which patients aged 12 years or older with mild asthma were randomly assigned (1:1:1) to placebo twice daily plus as-needed terbutaline 0·5 mg, placebo twice daily plus as-needed budesonide-formoterol 200-6 μg, or budesonide 200 μg twice daily plus as-needed terbutaline (ie, budesonide maintenance group). In this post-hoc analysis, we assessed the frequency of reliever use and the risk of a severe exacerbation in the 21 days after first use of more than two, four, six, or eight reliever inhalations in 24 h. SYGMA 1 is registered with ClinicalTrials.gov, NCT02149199, and is now complete. FINDINGS: Of 5721 patients enrolled in SYGMA 1, 3849 were randomly assigned to as-needed terbutaline (n=1280), as-needed budesonide-formoterol (n=1279), or budesonide maintenance (n=1290), of whom 3836 had evaluable data (n=1277 as-needed terbutaline, n=1277 as needed budesonide-formoterol, and n=1282 budesonide maintenance). Median reliever use was 0·32 (IQR 0·08-0·91) inhalations per day for the as-needed terbutaline group, 0·29 (0·07-0·72) for the as-needed budesonide-formoterol group, and 0·16 (0·04-0·52) for the budesonide maintenance group. Compared with as-needed terbutaline, after adjustment for age, sex, randomly assigned treatment, pre-study treatment group, baseline % predicted post-bronchodilator FEV1, and severe exacerbation in the 12 months before enrolment in the study, the hazard ratio (HR) for severe exacerbation in the 21 days after a single day with more than two as-needed inhalations was 0·27 (95% CI 0·12-0·58; p=0·0008) with as-needed budesonide-formoterol and 0·39 (0·19-0·79; p=0·0091) with budesonide maintenance; after a single day of more than four as-needed inhalations the HR was 0·24 (0·10-0·62; p=0·0030) with as-needed budesonide-formoterol and 0·30 (0·13-0·72; p=0·0065) with budesonide maintenance; and after a single day of more than six as-needed inhalations the HR was 0·14 (0·02-1·06; p=0·057) with as-needed budesonide-formoterol and 0·43 (0·14-1·26; p=0·12) with budesonide maintenance. HRs were not calculated for more than eight as-needed inhalations due to the small number of events. INTERPRETATION: In mild asthma, as-needed budesonide-formoterol reduces the short-term risk of severe exacerbations after a single day of higher use (more than two as-needed inhalations), even when overall use is infrequent. Use of an anti-inflammatory reliever might reduce the risk of short-term severe exacerbations by the timely provision of increased doses of as-needed inhaled corticosteroids and formoterol when symptoms occur. These findings should be further assessed in prospective randomised clinical trials. FUNDING: AstraZeneca.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. O'Byrne PM, FitzGerald JM, Bateman ED, et al. Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study. Lancet Respir Med. 2020. PMID: 33010810. doi:10.1016/S2213-2600(20)30416-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。